NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ · Manufacturing · Pharmaceutical preparations
$22.58−$0.1600 (−0.70%) on the dayAs of the close; data may be delayed.
NAMS price, last 12 months
Key stats
- Previous close
- $22.74
- Open
- $22.85
- Day range
- $22.35 – $23.00
- 52-week range
- $21.02 – $42.21
- Volume
- 1.1M
- Avg volume (20 days)
- 1.8M
- Market cap
- $2.7B
Performance
1W+0.4%
1M−17.6%
3M−32.1%
6M−27.7%
YTD−35.6%
1Y−15.6%
vs S&P 500, 1Y−32.4 pts
Technicals and fundamentals
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $2.7B